Corbus Pharmaceuticals recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Scleroderma News, 09/02/2015. (Also see Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.